Reference

Last reviewed: 28 Apr 2026
Sources cited: 10

Compound class~4,731 Da

Triple agonist — GLP-1 / GIP / Glucagon

Next-generation metabolic compound. Modified polypeptide backbone with fatty-acid conjugation for extended half-life. Exact sequence proprietary.

Retatrutide

Last verified: 2026-04-24

At a glance


Also known as	LY3437943, GGG tri-agonist
Class	Triple hormone receptor agonist — GLP-1, GIP, AND glucagon (first-in-class)
Typical route	Subcutaneous injection, once weekly
UK status	Not approved. Not legally available as a medicine in the UK. Phase 3 clinical trials ongoing (TRIUMPH programme). UK licensed availability is unlikely before 2028. Grey-market “research chemical” supply exists widely and is unlawful to sell for human use.
Plasma half-life	~6 days (long; enables weekly dosing)
Molecular weight	~4,731 Da
Developer	Eli Lilly & Company

What it is

Retatrutide is Eli Lilly’s next-generation obesity and diabetes drug — and on current evidence, it may be the most effective weight-loss compound ever developed. It adds a third mechanism (glucagon receptor agonism) to the GLP-1 and GIP agonism of tirzepatide, producing weight loss of up to 28.7% at 68 weeks in Phase 3 — substantially above tirzepatide’s ~21%.

Critical context for UK readers:

Retatrutide is not approved by the MHRA. It cannot be legally prescribed or dispensed in the UK.
Retatrutide is not approved by the FDA or EMA either. It is globally investigational as of April 2026.
Phase 3 TRIUMPH trials are ongoing. FDA New Drug Application submission is expected Q4 2026; FDA approval realistically late 2027 or early 2028; UK/EU approval likely 2028 or later.
UK grey-market supply is widespread. Research-chemical vendors sell retatrutide labelled “for research use only / not for human consumption” — a labelling convention that is legally permitted for the sale of the raw peptide but does not authorise human use.
The MHRA has been actively enforcing against illegal retatrutide production. The October 2025 East Midlands raid seized unlicensed retatrutide and tirzepatide pens. A February 2026 North Wales investigation is ongoing.

For most readers, the central tradeoff is straightforward: retatrutide is promising, the grey-market supply is risky, and the licensed pathway is still pending. The practical decision is whether to wait for regulated access or accept the uncertainty that comes with an investigational compound sourced outside clinical trials.

Mechanism

Retatrutide activates three receptors simultaneously, adding glucagon receptor agonism to tirzepatide’s GLP-1/GIP dual mechanism:

GLP-1 receptor activation (same as semaglutide): reduces appetite, slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon release in fed state
GIP receptor activation (same as tirzepatide): improves insulin sensitivity, preferentially reduces visceral fat
Glucagon receptor activation (new): increases energy expenditure, promotes fat oxidation and metabolic activity. Historically glucagon was thought of as the counter-regulatory hormone that raises blood glucose; retatrutide’s therapeutic window uses glucagon’s energy expenditure effects while other mechanisms counteract its glucose-raising effect.1

Why the triple mechanism produces more weight loss than tirzepatide:

Tirzepatide reduces intake (GLP-1) and improves fat handling (GIP). Retatrutide does both of those, and adds energy expenditure through the glucagon arm. Eating less and burning more, in one molecule.

The precision of the receptor ratio is the innovation. Retatrutide’s glucagon activity is carefully balanced against its GLP-1 activity so that net glucose control improves (GLP-1 effect dominates at the receptor ratio used) while metabolic rate increases (glucagon effect contributes without causing problematic hyperglycaemia).

Routes of administration

Subcutaneous injection (the only viable route)


Form in trials	Prefilled pens at 1, 2, 4, 8, 12 mg doses (investigational; not commercially available)
Frequency	Once weekly, same day each week
Onset	Appetite effects within days; weight loss measurable over weeks to months
Steady state	~4–5 weeks at each dose level
Equipment (in clinical trials)	Prefilled pen, similar to Mounjaro/Wegovy
Equipment (grey market)	Lyophilised powder requiring reconstitution with bacteriostatic water, insulin syringe — like research-chemical peptides, not like a licensed medicine

The investigational route is the same as other GLP-1 agonists — once-weekly subQ. In clinical trials, retatrutide is delivered via prefilled pens. In grey-market supply, it’s typically supplied as lyophilised powder and reconstituted by the user, similar to research-chemical BPC-157 or TB-500.

This is a meaningful practical difference for UK users: someone running retatrutide outside of clinical trials is reconstituting research-chemical peptide and self-administering, not using a pharmaceutical pen with titration guidance and clinical oversight.

Oral / sublingual / intranasal


Bioavailability	Essentially zero oral; no viable sublingual or nasal route
Typical dose (this route)	Not applicable

Retatrutide is a large peptide with albumin-binding modifications similar to semaglutide. It is not GI-stable. No meaningful oral, sublingual, or nasal route exists for this molecule.

Cross-route comparison

SubQ or nothing. Route choice for retatrutide is not a question. The question is whether you access it through clinical trial enrolment, named-patient routes (essentially unavailable), or grey market. Each pathway has very different legal, safety, and quality implications.

What the evidence says

Honest summary: retatrutide has the most impressive efficacy data of any weight-loss compound ever studied, but only from Phase 2 and early Phase 3 trials. Cardiovascular outcomes and long-term safety data are not yet available.

Phase 2 obesity trial (2023, NEJM)

338 adults with obesity without diabetes, 48 weeks
Doses: 1, 4, 8, 12 mg weekly (with escalation schedules)
Weight loss at 48 weeks:
1 mg: −7.2%
4 mg: −12.9%
8 mg: −17.3%
12 mg: −24.2%
Placebo: −2.1%
No plateau observed at 48 weeks at higher doses — weight was still declining, suggesting even greater effects with longer treatment
GI adverse events primarily during dose escalation; mostly mild-moderate

Phase 2 type 2 diabetes trial (2023, The Lancet)

281 participants with T2DM, 36 weeks primary endpoint
Doses: 0.5, 4, 8, 12 mg retatrutide; comparator: dulaglutide 1.5 mg
Weight loss at 36 weeks: 3.19% (0.5 mg) to 16.94% (12 mg) vs 3.00% placebo and 2.02% dulaglutide
HbA1c reduction: up to −2.02% at 12 mg vs −1.41% dulaglutide and essentially no change on placebo
GI adverse events occurred in 35% of retatrutide recipients — similar rate to dulaglutide comparator2

TRIUMPH Phase 3 programme (ongoing; initial readouts 2025–2026)

TRIUMPH is Eli Lilly’s Phase 3 programme — four initial registrational trials, expanding to seven trials with >5,800 total participants.

TRIUMPH-4 (December 2025 readout):

445 adults with obesity and knee osteoarthritis, without diabetes
68 weeks, 9 mg or 12 mg retatrutide vs placebo
Highest dose: 28.7% mean weight loss (equivalent to ~71 lbs / ~32 kg)
Significant proportion achieved ≥25%, ≥30%, ≥35% weight loss — response rates previously unseen in obesity trials
Substantial relief from osteoarthritis pain as secondary endpoint
GI adverse events consistent with Phase 2 pattern

TRANSCEND-T2D-1 (March 2026 readout):

Phase 3 in type 2 diabetes
Met primary and all key secondary endpoints
Participants lost up to 16.8% (36.6 lbs average) weight — as a secondary endpoint, with primary endpoint being HbA1c reduction
Superior A1C reduction and weight loss at 40 weeks vs placebo

MASLD (fatty liver) Phase 2a

Positive results for metabolic dysfunction-associated steatotic liver disease — adding another potential indication

Comparison with tirzepatide and semaglutide

Compound	Max mean weight loss	Mechanism	Regulatory (UK, Apr 2026)
Semaglutide (Wegovy)	~17%	GLP-1 only	Licensed
Tirzepatide (Mounjaro)	~21%	GLP-1 + GIP	Licensed
Retatrutide	~29%	GLP-1 + GIP + glucagon	Investigational — not licensed

The efficacy trajectory is clear — each added mechanism produces more weight loss. But licensing status matters: retatrutide’s extra 8 percentage points of weight loss comes at the cost of no MHRA approval, no clinical infrastructure, no licensed providers.

What the evidence doesn’t yet show

Long-term safety beyond ~18 months
Cardiovascular outcomes — no dedicated CV outcomes trial has read out yet. Retatrutide shows heart rate increases (5–10 bpm) and cardiac arrhythmias in 2–11% of participants (none serious). CV benefit/risk balance remains to be established.
Weight regain pattern on discontinuation — assumed to follow GLP-1/tirzepatide pattern (regain on stopping) but not formally studied
Use in special populations — elderly, renal impairment, hepatic impairment, adolescents

Typical use patterns

In clinical trials (the evidence-aligned pattern)

Standard Phase 2/3 titration:

Weeks	Dose
1–4	2 mg weekly
5–8	4 mg weekly
9–12	8 mg weekly
13+	12 mg weekly (if target dose)

Each step is 4 weeks minimum. Starting dose of 2 mg (vs 4 mg) dramatically reduces early GI events — nausea rates at 8 mg dropped from 60% in those who started at 4 mg to 17% in those who started at 2 mg. Titration speed matters for tolerability.

TRIUMPH-4 used a slower titration with stepwise escalation through more intermediate doses over a longer window — a lesson from Phase 2 that slower is better tolerated.

Community (“grey market”) dosing patterns

Users accessing research-chemical retatrutide typically follow variations of the clinical trial titration. Community-adapted protocols often:

Start lower (0.5–1 mg) than clinical trials, partly due to dose-precision limits with reconstituted powder and partly for extra caution
Escalate more slowly (6 weeks or more per step) than clinical protocols
Target doses in the 6–10 mg range rather than 12 mg, driven by tolerability and cost considerations
Use microdosing (1–2 mg weekly) for slower, sustained weight loss rather than maximum effect

The community microdose approach is interesting — not supported by trial evidence at those doses, but conceptually: if you can tolerate a low dose and get sustained weight loss, why chase higher doses? Phase 2 data showed even 4 mg produced ~13% weight loss, which is comparable to Wegovy at maximum dose.

Duration

Like tirzepatide and semaglutide, retatrutide is expected to require ongoing treatment for maintained effect. Discontinuation likely results in weight regain.

Stacking

Do not combine with GLP-1 agonists (semaglutide, tirzepatide, liraglutide) — same mechanism, additive risk, no additional benefit
Research-chemical peptides (BPC, KPV, MOTS-c, etc): no documented interactions; users frequently combine
Metformin / other diabetes medications: may need dose reduction (both for glucose lowering and weight loss effects)
SSRIs, SNRIs, LDN: no documented interactions

For sensitive systems

The sensitive-systems considerations for retatrutide are largely extrapolated from tirzepatide and semaglutide, because direct data in MCAS/POTS/ME-CFS/long-COVID populations are not available. Users in these populations accessing retatrutide are in genuinely uncharacterised territory.

Start approach for sensitive users.

0.5–1 mg weekly for 2–4 weeks before considering 2 mg step
Hold each subsequent dose for a minimum of 6 weeks (not the trial’s 4 weeks)
Target the lowest effective dose, not the clinical protocol’s 8 mg or 12 mg maximum

Expected adjustment profile (from trial data + class extrapolation):

Nausea — dose-dependent, 14% at 1 mg up to 60% at 12 mg. Slower titration reduces this significantly.
Vomiting, diarrhoea, constipation — as for GLP-1 class
Heart rate increase of 5–10 bpm — documented in trials; peaks at week 24. This is more than semaglutide/tirzepatide and may matter for POTS users.
Cardiac arrhythmias — 2–11% in trials vs 2% placebo; none classified as serious, but the signal is larger than semaglutide’s
Fatigue during early weeks
Injection site reactions — typically mild

For POTS users: the heart rate and arrhythmia signals for retatrutide are larger than for semaglutide or tirzepatide. Users with POTS should treat this as a meaningful consideration rather than dismissing it as “same as other GLP-1s.” Start very low, titrate very slowly, monitor HR daily if possible.

For MCAS / histamine-sensitive users: no specific histamine activity documented; shares GI slowing concerns with other GLP-1s.

For ME/CFS / chronic fatigue: the early-weeks fatigue concern applies. If already at low energy baseline, the cumulative cost of GI side effects and early fatigue may be significant.

For gastroparesis: retatrutide slows gastric emptying; likely additive to existing gastroparesis. Relative contraindication.

Interactions worth considering:

Other GLP-1 agonists: do not combine — same class
Insulin and sulphonylureas (if diabetic): hypoglycaemia risk; requires dose adjustment
Beta-blockers (for POTS/cardiovascular): may be useful to attenuate retatrutide’s heart rate effect; no documented adverse interaction
Oral medications: slowed gastric emptying affects absorption
Oral contraceptives: as for tirzepatide — consider barrier backup during dose escalations
Research-chemical peptides: no documented interactions

Important honest note on sensitive populations: retatrutide is the most powerful weight-loss compound available. It is also the least-studied of the three GLP-1 compounds in this encyclopedia and the only one without a licensed pathway. Sensitive users considering retatrutide should weigh whether the additional weight-loss potential over tirzepatide or semaglutide justifies the additional safety uncertainty and the supply-chain uncertainty of grey-market sourcing.

Reasonable expectations

Onset. Same pattern as other GLP-1 agonists — appetite effects within days, measurable weight loss from weeks 4–8, significant weight loss at 20–40 weeks. Given retatrutide’s higher effect size, significant weight loss comes faster and larger than on tirzepatide or semaglutide.

Response rate. Response rates in Phase 3 TRIUMPH-4 were higher than any previous obesity trial — significant fractions achieved ≥25%, ≥30%, ≥35% weight loss, which was essentially unheard of before retatrutide.

What the evidence actually supports (Phase 2 + early Phase 3).

Up to ~29% mean weight loss at highest tested dose over ~68 weeks
Dose-response continues with no ceiling at 12 mg in 48-week data — unclear where effects plateau
HbA1c reduction superior to dulaglutide in T2DM
Metabolic dysfunction-associated steatotic liver disease (MASLD) improvement in Phase 2a
Reduced osteoarthritis pain as secondary benefit (probably from weight reduction)

What the evidence does not yet show.

Cardiovascular outcomes — dedicated trial not yet reported
Long-term safety beyond ~2 years
Safety and efficacy in elderly, renally impaired, hepatically impaired, adolescents
Effects after discontinuation — assumed to regain, not yet directly studied

What not to expect.

A licensed UK medicine before 2028
Pharmaceutical-grade quality from grey-market sources
Clinical oversight equivalent to licensed GLP-1 use
Evidence base matching tirzepatide or semaglutide — retatrutide is 2–3 years behind them in real-world data

Cost

Retatrutide is not available through licensed UK pharmacy channels. There are no legitimate private prescription costs to quote. We’re not publishing grey-market prices because doing so would function as market intelligence for an illegal trade.

The legitimate pathways to retatrutide access in the UK:

Clinical trial participation — if you meet eligibility for a UK-recruiting TRIUMPH trial site. The ISRCTN and ClinicalTrials.gov registries list recruiting trials. This is free (trial medication is provided) and includes comprehensive clinical oversight.
Named-patient “specials” import — extremely rare for retatrutide; would require specialist referral, compelling clinical rationale, and individual import authorisation. Not a normal access route.
Wait for licensed approval — estimated 2028+ in the UK. Private prescription pricing likely to be premium to tirzepatide given the mechanism advancement — perhaps £250–450/month at standard doses, extrapolating from other premium GLP-1 pricing.

On the grey market (for context only): retatrutide research-chemical supply exists widely through the same vendors selling BPC-157, TB-500, and similar compounds. Prices vary dramatically by quantity and vendor. Quality control issues documented include under-potency, bacterial contamination, endotoxin elevation, and incorrect sequence.

Reconstitution

This section covers reconstitution of research-chemical retatrutide. Trial-supplied retatrutide arrives as a prefilled pen and requires no preparation — if that’s your route, skip this section. Almost everyone outside a clinical trial is reconstituting lyophilised powder, and the math matters because retatrutide is dosed across a wide range and there are two genuinely different practitioner camps.

What’s in the box

Research-chemical retatrutide ships as lyophilised (freeze-dried) white powder in a glass vial, typically 5 mg or 10 mg per vial. Some vendors sell 2 mg or 15 mg vials but those are less common. The vial is sealed with a rubber stopper and aluminium crimp; you don’t open it, you draw through the stopper.

You’ll also need:

Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol, the standard diluent for multi-dose injectable peptides. Sometimes labelled “bacteriostatic 0.9% sodium chloride” — same thing functionally for our purposes. Ordinary saline or sterile water will work for a single-use vial but is not bacteriostatic, so the reconstituted vial expires fast.
Insulin syringe (U-100) — typically 1 mL with 29G–31G needle. Marked in “units” rather than mL: 100 units = 1 mL, so each unit = 0.01 mL.
A larger syringe (3 mL or 5 mL) for transferring the BAC water into the vial. Insulin syringes draw too slowly through stoppers for the initial fill.
Alcohol wipes, a clean working surface, and somewhere to record what you did.

The three practitioner camps

Retatrutide users split into three patterns, and the reconstitution math is different for each.

The standard titration camp follows the trial protocol: start at 2 mg weekly, escalate every 4–6 weeks through 4 mg, 8 mg, 12 mg, looking for maximum weight loss. One injection per week. This camp typically buys 10 mg vials and runs through them in 1–5 weeks depending on the dose step.

The split-dosing camp takes the same total weekly dose but divides it into 2–3 smaller injections across the week — for example, 6 mg/week becomes 2 mg every 2–3 days. The community often calls this “microdosing,” which is a misnomer: real microdosing means an order of magnitude below the therapeutic range, and split dosing keeps the total weekly dose unchanged. Only the per-injection peak is smaller. The point is to flatten peak-to-trough swings: lower peaks mean less GI side effect, smoother appetite suppression. Practitioners report this is most useful during early titration weeks when swings are largest.

The sustained-low-dose camp runs absolute weekly doses at the low end of the studied range — typically 0.5–2 mg/week — held flat over a cycle rather than escalated. Phase 2 data showed 1 mg/week produced ~7% weight loss over 48 weeks (comparable to standard-dose semaglutide), and this camp accepts the slower curve in exchange for milder side effects, lower cost per week, and the ability to stop and restart without significant withdrawal/regain dynamics. This is also sometimes called “microdosing” in the community, but it’s the low end of normal dosing rather than a true microdose.

All three patterns are real and used widely. None is “wrong” — they’re different goals. The reconstitution math just needs to match the goal.

The math

For research-chem reconstitution, the rule is: pick a BAC volume that puts each injection at a syringe mark you can read accurately. U-100 insulin syringe markings get hard to read below ~5 units (0.05 mL), so aim higher than that for accuracy.

Standard titration — 10 mg vial, 2 mL BAC water

Concentration: 5 mg/mL (5,000 mcg/mL)
2 mg weekly = 0.4 mL = 40 units
4 mg weekly = 0.8 mL = 80 units
8 mg weekly = 1.6 mL = 160 units (over a single 100-unit syringe — see split dosing below, or use a 1 mL syringe that marks to full 1 mL)
12 mg weekly = 2.4 mL = the whole vial. Impractical at this concentration; reconstitute with less BAC for higher concentration (e.g. 10 mg + 1.2 mL = ~8.3 mg/mL → 12 mg = 1.44 mL = 144 units, still requiring a larger syringe).

Split dosing — 10 mg vial, 2 mL BAC water

Same 5 mg/mL concentration; same vial; the math is per-injection rather than per-week.
6 mg/week as 2 mg every 2–3 days = 0.4 mL = 40 units, three times a week
8 mg/week as 4 mg twice weekly = 0.8 mL = 80 units, twice weekly
12 mg/week as 6 mg twice weekly = 1.2 mL = 120 units twice weekly (over the 100-unit mark; either reconstitute denser or accept a 1 mL syringe)

The split-dosing camp tends to settle on twice-weekly because it’s simpler than three injections, and reports the GI benefit is most noticeable in the first 8–12 weeks of titration when peaks are highest.

Sustained low dose — 5 mg vial, 2.5 mL BAC water

Concentration: 2 mg/mL (2,000 mcg/mL)
0.5 mg (500 mcg) weekly = 0.25 mL = 25 units
1 mg weekly = 0.5 mL = 50 units
2 mg weekly = 1 mL = 100 units

Sustained low dose — 5 mg vial, 1 mL BAC water

Concentration: 5 mg/mL
0.5 mg (500 mcg) weekly = 0.1 mL = 10 units (right at the readability limit; the 2.5 mL dilution above is friendlier)
1 mg weekly = 0.2 mL = 20 units
2 mg weekly = 0.4 mL = 40 units

The Peptrax Vial Plan calculator handles the same math interactively — enter your vial size, BAC volume, and weekly dose, and it returns draw volume, doses per vial, and depletion timing.

Reconstitution procedure

Wipe the rubber stopper of the lyophilised vial and the BAC water vial with alcohol.
Draw the chosen volume of BAC water into the larger syringe.
Insert the needle into the lyophilised vial at an angle, with the tip touching the inside wall of the vial above the powder. Inject the water slowly down the inside of the vial, not directly onto the powder. Forcing water onto lyophilised peptide can denature it.
Leave the vial undisturbed for 1–2 minutes. Do not shake. Gently swirl if needed; the powder will dissolve on its own. Shaking creates foam and can fragment peptide chains.
Once the solution is clear, label the vial: compound, concentration, reconstitution date.
Store refrigerated (2–8°C / 36–46°F).

Some practitioners pass the reconstituted solution through a 0.22 µm syringe filter as a belt-and-braces sterility step. With a sealed lyophilised vial and clean technique, this is optional rather than standard — the vial was sterile when sealed, and your reconstitution adds bacteriostatic water containing benzyl alcohol. Filtering is more relevant if you’re concerned about a specific vendor’s lyophilisation quality or if you’re using plain (non-bacteriostatic) sterile water for a single-use prep.

Storage and stability

Reconstituted retatrutide stability is genuinely uncertain in the public literature. Reasonable reads cluster around three points:

Conservative: 1–2 weeks refrigerated. Some research-supply vendors give this as the safe window, citing peptide degradation kinetics rather than direct stability studies.
Middle: 2–4 weeks refrigerated. The most commonly cited range across community sources and peptide vendors.
Optimistic: ~30 days refrigerated. Drawn partly from Lilly’s pen shelf life (Mounjaro/Zepbound: 21–30 days at room temperature once opened, longer refrigerated) and partly from peptide-class generalisations. This is plausible but the pens contain stabilisers that grey-market reconstitutions don’t.

The honest middle is 2–4 weeks refrigerated at 2–8°C. Some practitioners run vials to 30 days; the dose math holds but degradation may have started. Discard sooner if the solution clouds, changes colour, or develops particulates.

Store at the back of the refrigerator where the temperature is most stable, not in the door. Do not freeze — ice crystal formation disrupts peptide structure and reduces potency on thaw.

If you reconstitute with plain sterile water instead of BAC water, the vial is single-use — discard within 24 hours because there’s no preservative. This is a common mistake among first-time reconstituters.

The stability constraint matters most for the sustained-low-dose camp. A 5 mg vial dosed at 0.5 mg/week is 10 weeks of theoretical doses but only ~2–4 weeks of stable solution — so you’ll discard 60–80% of the vial. That’s the trade-off for fine-grained dose control. Smaller vials (2 mg) help, but they’re less commonly stocked.

For a 10 mg vial dosed at 4 mg weekly, you have 2.5 weeks of doses — comfortably within stability. The titration camp rarely encounters this constraint in practice.

What gets miscalculated

The recurring grey-market reconstitution errors, in rough order of frequency:

Confusing mg, mcg, and units. 1 mg = 1,000 mcg. A “10-unit” dose on a U-100 syringe is 0.1 mL of solution, not 10 mcg of compound. The compound amount depends on your concentration.
Reading “units” as mg. “Take 10 units” is not “take 10 mg.” Units are a volume mark on the syringe.
Reusing reconstitution numbers across compounds. A reconstitution recipe for tirzepatide doesn’t translate to retatrutide — the vial sizes and weekly doses are different.
Underestimating shelf life loss. A 5 mg vial run at 0.5 mg/week sounds like 10 weeks of doses; at 2–4 week refrigerated stability, you’ll use 20–40% of the vial before discarding the rest. Plan for it or buy smaller vials.
Drawing dose by eye on insulin syringes below 5 units. The smallest readable mark on most U-100 syringes is 1 unit (0.01 mL); below ~5 units, drawing accuracy drops sharply. If your math returns a sub-5-unit dose, reconstitute with more BAC water to make the volume larger and easier to draw.

Areas of concern ⚠

The legal and supply-chain concern (unique to retatrutide)

This is the defining concern for this compound.

Legal framing for UK:

Retatrutide has no MHRA authorisation
Under the Human Medicines Regulations 2012, selling unlicensed medicine is a criminal offence
Buying unlicensed medicine for personal use is not typically prosecuted but is technically unlawful
The “research use only” labelling on research-chemical retatrutide is legally permitted for the sale of the raw peptide to genuine research laboratories; it does not authorise human use
MHRA has actively enforced against illegal retatrutide production (October 2025 East Midlands raid; February 2026 North Wales investigation ongoing)
ASA September 2025 enforcement notice: any direct or indirect reference to GLP-1 products in public-facing advertising violates UK law

Quality framing:

No MHRA oversight of grey-market product
No batch testing, no cold-chain guarantee, no purity verification at the point of sale
Documented contamination, under-potency, and counterfeit issues
“Looks like pharmaceutical retatrutide” does not mean “is pharmaceutical retatrutide”
Some grey-market retatrutide has been found to contain no active compound; some contains tirzepatide mislabelled; some contains actual retatrutide at incorrect potency

The practical compromise: some users accept these risks for access to the most effective weight-loss compound currently in trials. Others wait for licensed access. The key point is to understand the legal, quality, and safety uncertainty before treating grey-market supply as interchangeable with a regulated medicine.

Cardiovascular uncertainty

Heart rate increases of 5–10 bpm — meaningfully higher than semaglutide (2–3 bpm) or tirzepatide (similar to semaglutide range)
Cardiac arrhythmias in 2–11% — higher than other GLP-1s
No dedicated cardiovascular outcomes trial has reported yet
Until CV outcomes data is available, retatrutide cannot be considered established as cardiovascular-safe in the way semaglutide is via SELECT

Long-term safety is uncharacterised

Most trial data is 48–68 weeks
Real-world use beyond this duration exists only at the individual grey-market user level — no systematic long-term follow-up
Unknown effects on: bone density during rapid weight loss, thyroid long-term, muscle mass loss (likely significant given weight loss magnitude), metabolic adaptation

Glucagon mechanism-specific concerns

Glucagon receptor activation historically has raised concerns about increased hepatic glucose production and potential worsening of glucose control in some patients
Retatrutide’s balanced receptor ratio largely addresses this — overall trials show glucose improvement, not worsening
But mechanism-specific issues could emerge in specific populations (T1DM, brittle diabetes, glycogen storage disorders) with no data yet
Hepatic function: theoretically glucagon agonism could affect liver glycogen metabolism; Phase 2a MASLD data was actually positive, but this is an area for long-term monitoring

Rapid weight loss complications (same as tirzepatide/semaglutide, potentially more pronounced)

Gallstones — probably higher absolute incidence given larger weight loss magnitudes
Muscle mass loss — a larger practical concern at 25%+ weight loss than at 15% weight loss
Nutritional deficiencies — at this magnitude of appetite suppression, essential nutrient intake needs deliberate attention
Facial volume loss / loose skin — proportional to total weight loss
Hair loss / telogen effluvium — associated with rapid weight loss from any cause

Populations where retatrutide is contraindicated or high-risk

Personal or family history of medullary thyroid carcinoma (MTC) — class effect warning, contraindicated
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — contraindicated
Pregnancy — contraindicated; no pregnancy safety data at all for retatrutide
Severe cardiovascular disease — until CV outcomes data available, caution until explicit evidence
Significant arrhythmia history — given the arrhythmia signal in trials
Severe gastroparesis — relative contraindication
Type 1 diabetes — not studied; mechanism-specific concerns with glucagon component
Under 18 — no paediatric data
Severe renal or hepatic impairment — no data; avoid
Eating disorders (active anorexia, active bulimia) — the appetite suppression is severe and contraindicated

The dependency concern (same as tirzepatide/semaglutide, compounded by supply uncertainty)

Like other GLP-1 agonists, retatrutide is expected to require ongoing treatment for maintained effect. For users relying on grey-market supply, this creates a compound issue: what happens if the supply dries up?

MHRA enforcement could disrupt supply at any time
Licensed approval (2028+) could shift pricing and availability dramatically
Individual vendors can disappear without notice

Starting retatrutide is effectively a commitment to either continue it, transition to licensed tirzepatide/semaglutide, or accept weight regain — all of which require planning.

FDA / regulatory status

Jurisdiction	Status	Last verified
UK (MHRA)	Not approved. Investigational only. Phase 3 TRIUMPH trials ongoing at UK sites. Named-patient imports theoretically possible but not standard.	2026-04-24
US (FDA)	Not approved. NDA submission expected Q4 2026; realistic approval late 2027–early 2028.	2026-04-24
EU (EMA)	Not approved. Expected to follow FDA timeline.	2026-04-24
Anywhere	Not licensed anywhere as of April 2026.	2026-04-24
WADA (sport)	Not explicitly listed but would fall under peptide hormone / growth factor prohibitions	2026-04-24

Timeline for UK availability (projected):

Q4 2026 – Q1 2027: Eli Lilly submits NDA to FDA and MAA to EMA/MHRA
Late 2027 – Q1 2028: US FDA approval realistic
2028: UK/EU approval realistic; private prescription availability likely
2029+: possible NHS pathway via Tier 3 specialist services (slower than private)

Narrative. Retatrutide is the clearest case in this encyclopedia of a high-promise compound that remains investigational while grey-market demand runs ahead of approval. For UK readers, the legitimate pathways are clinical trial participation, rare named-patient imports, or waiting for approval.

For UK readers: retatrutide is legally an investigational medicine. You cannot obtain it through any UK licensed pharmacy. Research-chemical retatrutide exists but remains unlicensed medicine under UK law.

What to track in Peptrax

Retatrutide is the GLP-1-class compound where the licensed-vs-unlicensed framing matters most, and the app’s role differs accordingly. For users in legitimate clinical trials, the trial protocol is doing most of the structured tracking — the relevant Peptrax fields are personal context the trial is not capturing: subjective appetite, energy, mood, and any quality-of-life observations that don’t fit the trial’s primary endpoints. For users on grey-market research-chemical retatrutide, the situation is genuinely different: there is no clinician, no titration support, no GI side-effect protocol, and the app’s job is to surface concerning patterns rather than to optimise.

Whichever path, the core tracking is recognisable from tirzepatide and semaglutide — weekly weight, waist, GI symptoms on a 0–5 scale, appetite notes, dose schedule. Retatrutide’s triple-agonist mechanism produces a more aggressive weight-loss curve in the trials, which means more aggressive side-effect potential at the same milligram dose; logging GI symptoms against dose changes is doubly important if you’re titrating without prescriber support.

Because the compound is investigational, logging which study (if applicable), what dose the protocol specifies, and what’s actually being administered is the literacy bar. For grey-market users, the honest tracking question is harder: source, batch (if available), reconstitution date, and any concerning symptoms — and a written stop criterion before starting, because there is no prescriber to call when something feels wrong. The app cannot substitute for medical care, but it can hold the timeline that makes a later medical conversation possible.

For personal tracking and informational purposes only — not medical advice.